Ocular Therapeutix (NASDAQ: OCUL) reported Q2 EPS of ($0.64), $0.08 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $438 thousand versus the consensus estimate of $490 thousand.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.